Artificial Intelligence has suddenly gone from the fringes of science to being everywhere. So how did we get here? And where's this all heading? In this new series of Science Friction, we're finding out.
…
continue reading
Player FM - Internet Radio Done Right
40 subscribers
Checked 3M ago
เพิ่มแล้วเมื่อ eightปีที่ผ่านมา
เนื้อหาจัดทำโดย MediCom Oncology เนื้อหาพอดแคสต์ทั้งหมด รวมถึงตอน กราฟิก และคำอธิบายพอดแคสต์ได้รับการอัปโหลดและจัดหาให้โดยตรงจาก MediCom Oncology หรือพันธมิตรแพลตฟอร์มพอดแคสต์ของพวกเขา หากคุณเชื่อว่ามีบุคคลอื่นใช้งานที่มีลิขสิทธิ์ของคุณโดยไม่ได้รับอนุญาต คุณสามารถปฏิบัติตามขั้นตอนที่แสดงไว้ที่นี่ https://th.player.fm/legal
Player FM - แอป Podcast
ออฟไลน์ด้วยแอป Player FM !
ออฟไลน์ด้วยแอป Player FM !
พอดคาสต์ที่ควรค่าแก่การฟัง
สปอนเซอร์
Vicki Sokolik refuses to be an Ostrich. Her son brought to her attention the crisis of unhoused youth — youth unhoused, not living with a parent/guardian, and not in foster care — in America, and she has been fighting to support this vulnerable population every since. Most active in Tampa Bay, Florida, Vicki is the founder and CEO of the nonprofit Starting Right, Now, which removes barriers for unaccompanied homeless youth to cultivate long-term well-being and self-sufficiency. She is also the author of the new book, “If You See Them: Young, Unhoused, and Alone in America.” Vicki Sokolik joined host Jay Ruderman to discuss the many ways unhoused youth fall through the cracks in our society, how her organization helps them, and also how to build trust with people who could use your help. Episode Chapters (00:00) Intro (01:10) Vicki’s origin story (02:40) What is “unhoused youth?” (06:40) What should a person do if they worry they see an unhoused youth? (08:19) How have conversations around unhoused youth changed in Vicki’s 20 years working with them? (11:02) How do people get the word out and help unhoused youth? (14:55) Vicki’s new book (16:48) How Vicki builds trust (20:10) What do students receive at Starting Right, Now? (22:58) How does Vicki balance advocacy and direct support? (27:53) Starting Right, Now alumni (29:10) Goodbye For video episodes, watch on www.youtube.com/@therudermanfamilyfoundation Stay in touch: X: @JayRuderman | @RudermanFdn LinkedIn: Jay Ruderman | Ruderman Family Foundation Instagram: All About Change Podcast | Ruderman Family Foundation To learn more about the podcast, visit https://allaboutchangepodcast.com/…
The new FDA approval of pembrolizumab for cHL
Manage episode 175168813 series 1375096
เนื้อหาจัดทำโดย MediCom Oncology เนื้อหาพอดแคสต์ทั้งหมด รวมถึงตอน กราฟิก และคำอธิบายพอดแคสต์ได้รับการอัปโหลดและจัดหาให้โดยตรงจาก MediCom Oncology หรือพันธมิตรแพลตฟอร์มพอดแคสต์ของพวกเขา หากคุณเชื่อว่ามีบุคคลอื่นใช้งานที่มีลิขสิทธิ์ของคุณโดยไม่ได้รับอนุญาต คุณสามารถปฏิบัติตามขั้นตอนที่แสดงไว้ที่นี่ https://th.player.fm/legal
Listen as Dr. Anas Younes covers the new FDA approval of pembrolizumab for patients with cHL.
…
continue reading
53 ตอน
Manage episode 175168813 series 1375096
เนื้อหาจัดทำโดย MediCom Oncology เนื้อหาพอดแคสต์ทั้งหมด รวมถึงตอน กราฟิก และคำอธิบายพอดแคสต์ได้รับการอัปโหลดและจัดหาให้โดยตรงจาก MediCom Oncology หรือพันธมิตรแพลตฟอร์มพอดแคสต์ของพวกเขา หากคุณเชื่อว่ามีบุคคลอื่นใช้งานที่มีลิขสิทธิ์ของคุณโดยไม่ได้รับอนุญาต คุณสามารถปฏิบัติตามขั้นตอนที่แสดงไว้ที่นี่ https://th.player.fm/legal
Listen as Dr. Anas Younes covers the new FDA approval of pembrolizumab for patients with cHL.
…
continue reading
53 ตอน
ทุกตอน
×M
MediCom Oncology Clinical Pearls Podcasts
Dr. Perl provides a brief summary of what is on the horizon for FLT3 inhibitors in AML.
Dr. Sallman describes a patient case demonstrating promise in the further study and potential use of CAR T-cell therapy for patients with AML.
M
MediCom Oncology Clinical Pearls Podcasts
Dr. Perl gives guidance on providing optimal patient therapy when prescribing midostaurin with a strong CYP3A4 inhibitor.
M
MediCom Oncology Clinical Pearls Podcasts
1 How to proceed with a patient who presents with idiopathic cytopenia of undetermined significance 3:58
In this audio activity, Dr. Goldberg describes his approach to patients with idiopathic or clonal cytopenias of undetermined significance (ICUS and CCUS).
M
MediCom Oncology Clinical Pearls Podcasts
Listen as Dr. Goldberg explains his approach to iron chelation therapy in patients who are, or may be within the next 5-10 years, eligible for transplant.
M
MediCom Oncology Clinical Pearls Podcasts
Hematopathologist Dr. Khoury presents a case snapshot showing the complexities of diagnosing AML, describing the importance of morphology, flow cytometry, cytogenetics, and molecular diagnostics.
M
MediCom Oncology Clinical Pearls Podcasts
Dr. O'Reilly discusses the new subcategories of pancreatic cancer that have emerged, and which are laying the groundwork for a biomarker-driven approach to therapy.
M
MediCom Oncology Clinical Pearls Podcasts
1 What are the unique aspects of pancreas cancer that lead to the development of novel therapeutics? 2:40
Dr. O'Reilly discusses the unique pathophysiology of pancreas cancer that must be considered in the development of novel therapeutics.
M
MediCom Oncology Clinical Pearls Podcasts
Listen as Dr. Goldberg discusses, in just under two minutes, the predictors of response to lenalidomide in a non-del(5q) MDS patient.
Listen as Dr. Matasar discusses the pros and cons of radiation therapy, and who should be offered this therapy.
M
MediCom Oncology Clinical Pearls Podcasts
1 What defines high-quality survivorship care for patients treated for classical Hodgkin lymphoma? 3:01
Listen as Dr. Matasar discusses survivorship care for patients who have been treated for classical Hodgkin lymphoma, including late effects of treatment.
M
MediCom Oncology Clinical Pearls Podcasts
Dr. Jacob Laubach discusses second primary malignancies associated with lenalidomide maintenance in the transplant and post-transplant setting.
M
MediCom Oncology Clinical Pearls Podcasts
Dr. Laubach discusses the impact of consolidation therapy in patients post-transplant, referencing results of the CTN StaMINA trial.
M
MediCom Oncology Clinical Pearls Podcasts
Dr. Jacob Laubach discusses bortezomib as an alternate strategy to lenalidomide for maintenance therapy in patients with multiple myeloma.
M
MediCom Oncology Clinical Pearls Podcasts
Listen as Dr. Matasar discusses the future role of brentuximab vedotin in patients with newly diagnosed classical Hodgkin lymphoma.
ขอต้อนรับสู่ Player FM!
Player FM กำลังหาเว็บ